Thu Nov 07 00:00:00 UTC 2024: ## RNA Editing: A New Era in Precision Medicine?
**Boston, MA (November 7, 2024) –** The field of gene editing is experiencing a revolution with the rise of RNA editing, a technique that allows scientists to correct errors in messenger RNA (mRNA) before the cell reads it to make proteins.
This breakthrough, pioneered by Wave Life Sciences in Massachusetts, has the potential to treat a range of debilitating disorders, including α-1 antitrypsin deficiency (AATD), Huntington’s disease, Duchenne muscular dystrophy, and even forms of obesity.
RNA editing works by utilizing a naturally occurring enzyme called adenosine deaminase acting on RNA (ADAR) which converts adenosine, a building block of RNA, into inosine. This change is detected by the cell as an error, prompting it to correct the mRNA sequence, ultimately leading to the production of normal proteins.
Wave Life Sciences has successfully used this technology to treat AATD, a genetic disorder that affects the liver and lungs. Their therapy, dubbed WVE-006, uses a guide RNA (gRNA) to direct ADAR enzymes to specific mutations in the SERPINA1 gene, which produces α-1 antitrypsin.
This approach offers significant advantages over traditional DNA editing, which permanently alters the genome. RNA editing is temporary, allowing doctors to stop the therapy if needed and minimizing long-term risks. Additionally, ADAR enzymes are already present in the human body, reducing the risk of allergic reactions.
Despite its potential, RNA editing faces challenges, including the need to improve its specificity and the transient nature of its effects. Scientists are working on developing more accurate gRNAs and exploring alternative delivery methods.
Despite these challenges, the future looks promising for RNA editing. Several biotechnology companies are actively developing therapies for various diseases, attracting significant interest from large pharmaceutical firms.
“As research and clinical trials advance,” says Manjeera Gowravaram, a PhD in RNA biochemistry, “it seems like only a matter of time before RNA editing becomes a fixture of the gene-editing toolkit in clinical practice.”
First Piper 